CVM
Price
$9.45
Change
+$1.27 (+15.53%)
Updated
Aug 1 closing price
Capitalization
48.53M
HBIO
Price
$0.44
Change
-$0.03 (-6.38%)
Updated
Aug 1 closing price
Capitalization
184.01M
4 days until earnings call
Interact to see
Advertisement

CVM vs HBIO

Header iconCVM vs HBIO Comparison
Open Charts CVM vs HBIOBanner chart's image
Cel-Sci
Price$9.45
Change+$1.27 (+15.53%)
Volume$547.9K
Capitalization48.53M
Harvard Bioscience
Price$0.44
Change-$0.03 (-6.38%)
Volume$442.79K
Capitalization184.01M
CVM vs HBIO Comparison Chart in %
Loading...
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL).

Industry description

Few industries pique investor interest like the high-risk, high-reward biotechnology sector. It is not unusual for a biotech company’s stock to soar in value following the development of a successful product...even if it is just as likely that tens of millions of dollars in research will lead to nothing substantial. Biotech companies earn headlines for developing lifesaving and (potentially) massively lucrative treatments for illness, but the industry’s scope extends beyond healthcare to food and agriculture, industrial processing, and more. Any company producing technology that incorporates biological organisms falls within the sector. The search for the next big thing in biotech may come with risk, but investors have reason for optimism. Biotech products like DNA sequencing and gene therapy are experiencing increased demand and decreasing prices, while rising populations around the world mean demand for food and agricultural products resistant to environmental factors. Biotech’s biggest names include multinational corporations like Johnson & Johnson, Amgen, and Roche, who each sport market capitalizations in the hundreds of billions of dollars. With new government rules opening China as a market for new treatments, the biotech sector holds significant growth potential – and corresponding profitability for investors.

Market Cap

The average market capitalization across the biotechnology Theme is 7B. The market cap for tickers in the group ranges from 658 to 220.19B. TMO holds the highest valuation in this group at 220.19B. The lowest valued company is MTEM at 658.

High and low price notable news

The average weekly price growth across all stocks in the biotechnology Theme was 5%. For the same Theme, the average monthly price growth was 7%, and the average quarterly price growth was 20%. MRSN experienced the highest price growth at 2,039%, while ADAP experienced the biggest fall at -77%.

Volume

The average weekly volume growth across all stocks in the biotechnology Theme was -1%. For the same stocks of the Theme, the average monthly volume growth was 73% and the average quarterly volume growth was 201%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 76
Price Growth Rating: 56
SMR Rating: 88
Profit Risk Rating: 90
Seasonality Score: -20 (-100 ... +100)

Notable companies

The most notable companies in this group are Cel-Sci Corp (ASE:CVM).

Market Cap

The average market capitalization across the group is 116.27M. The market cap for tickers in the group ranges from 48.53M to 184.01M. HBIO holds the highest valuation in this group at 184.01M. The lowest valued company is CVM at 48.53M.

High and low price notable news

The average weekly price growth across all stocks in the group was -4%. For the same group, the average monthly price growth was 136%, and the average quarterly price growth was -47%. CVM experienced the highest price growth at 15%, while HBIO experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the group was -75%. For the same stocks of the group, the average monthly volume growth was 124% and the average quarterly volume growth was 1,791%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 99
P/E Growth Rating: 25
Price Growth Rating: 49
SMR Rating: 98
Profit Risk Rating: 100
Seasonality Score: -12 (-100 ... +100)
VS
CVM vs. HBIO commentary
Aug 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVM is a Hold and HBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 02, 2025
Stock price -- (CVM: $9.45 vs. HBIO: $0.44)
Brand notoriety: CVM: Notable vs. HBIO: Not notable
CVM represents the Biotechnology, while HBIO is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CVM: 54% vs. HBIO: 3%
Market capitalization -- CVM: $48.53M vs. HBIO: $184.01M
CVM [@Biotechnology] is valued at $48.53M. HBIO’s [@Medical Specialties] market capitalization is $184.01M. The market cap for tickers in the [@Biotechnology] industry ranges from $213.98B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B. The average market capitalization across the [@Medical Specialties] industry is $8.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVM’s FA Score shows that 0 FA rating(s) are green whileHBIO’s FA Score has 1 green FA rating(s).

  • CVM’s FA Score: 0 green, 5 red.
  • HBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, CVM is a better buy in the long-term than HBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVM’s TA Score shows that 5 TA indicator(s) are bullish while HBIO’s TA Score has 5 bullish TA indicator(s).

  • CVM’s TA Score: 5 bullish, 4 bearish.
  • HBIO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CVM is a better buy in the short-term than HBIO.

Price Growth

CVM (@Biotechnology) experienced а +15.24% price change this week, while HBIO (@Medical Specialties) price change was -22.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.14%. For the same industry, the average monthly price growth was +15.55%, and the average quarterly price growth was +36.18%.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.56%. For the same industry, the average monthly price growth was -2.26%, and the average quarterly price growth was -4.37%.

Reported Earning Dates

CVM is expected to report earnings on May 15, 2025.

HBIO is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical Specialties (-2.56% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HBIO($184M) has a higher market cap than CVM($48.5M). CVM YTD gains are higher at: -21.230 vs. HBIO (-79.332). HBIO has higher annual earnings (EBITDA): 8.03M vs. CVM (-21.96M). HBIO has more cash in the bank: 4.28M vs. CVM (1.92M). CVM has less debt than HBIO: CVM (10.5M) vs HBIO (42.8M). HBIO has higher revenues than CVM: HBIO (112M) vs CVM (0).
CVMHBIOCVM / HBIO
Capitalization48.5M184M26%
EBITDA-21.96M8.03M-273%
Gain YTD-21.230-79.33227%
P/E RatioN/AN/A-
Revenue0112M-
Total Cash1.92M4.28M45%
Total Debt10.5M42.8M25%
FUNDAMENTALS RATINGS
CVM vs HBIO: Fundamental Ratings
CVM
HBIO
OUTLOOK RATING
1..100
275
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
3464
P/E GROWTH RATING
1..100
492
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CVM's Valuation (98) in the Biotechnology industry is in the same range as HBIO (100). This means that CVM’s stock grew similarly to HBIO’s over the last 12 months.

CVM's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as HBIO (100). This means that CVM’s stock grew similarly to HBIO’s over the last 12 months.

HBIO's SMR Rating (98) in the Biotechnology industry is in the same range as CVM (99). This means that HBIO’s stock grew similarly to CVM’s over the last 12 months.

CVM's Price Growth Rating (34) in the Biotechnology industry is in the same range as HBIO (64). This means that CVM’s stock grew similarly to HBIO’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is somewhat better than the same rating for CVM (49). This means that HBIO’s stock grew somewhat faster than CVM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVMHBIO
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 9 days ago
73%
Declines
ODDS (%)
Bearish Trend 26 days ago
90%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
UNCHF7.070.15
+2.17%
Unicharm Corp.
AVACF0.03N/A
N/A
Avance Gas Holding Ltd.
EDDYF0.05N/A
N/A
EDISON LITHIUM CORP.
TMRAY13.82-0.19
-1.36%
Tomra Systems A/S/A
MLGF20.26-0.75
-3.57%
Malaga Financial Corp.

CVM and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CVM has been loosely correlated with NRXS. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if CVM jumps, then NRXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVM
1D Price
Change %
CVM100%
+15.53%
NRXS - CVM
58%
Loosely correlated
-4.58%
MDGL - CVM
43%
Loosely correlated
-0.11%
CYTK - CVM
40%
Loosely correlated
-2.52%
ADXN - CVM
39%
Loosely correlated
-1.22%
EYPT - CVM
38%
Loosely correlated
-1.12%
More

HBIO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
-6.36%
IRMD - HBIO
51%
Loosely correlated
+13.42%
A - HBIO
37%
Loosely correlated
-1.14%
ICUI - HBIO
36%
Loosely correlated
-0.79%
ANGO - HBIO
35%
Loosely correlated
-3.39%
MTD - HBIO
35%
Loosely correlated
-2.95%
More